Mylan Eylea Biosimilar Gets Green Signal For Trials In India
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.
You may also be interested in...
South Korean biotech Alteogen is progressing the development of its Eylea biosimilar both at home and abroad, with the hope of becoming a global first mover with its version in wet AMD, backed by formulation and manufacturing patents.
Intas Pharmaceuticals has claimed that certain adverse events reported with its Lucentis biosimilar were not caused by “qualitative aspects” of the product and that physicians have since “very satisfactorily” used subsequent batches of the vascular endothelial growth factor inhibitor in India.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.